Navigation Links
Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
Date:3/29/2011

als of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM™ are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no oblig
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
11. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... State spending on information technology may soon be subject ... costing tens of millions of dollars each, have failed ... and representative Suzanne Jeskewitz, co-chairs of the Joint Audit ... developed or renovated recently are inefficient or non-functional, and ...
... citywide wireless network in Milwaukee, the surrounding communities of ... , ,Waukesha and Wauwatosa are already being pitched by ... the city of Madison. Milwaukee's network is being built ... the deals established so far, the city is essentially ...
... At $2.5 million per 30-second spot, the average 2006 ... TV advertising has never been more affordable for small ... Spot Runner , it's possible to implement a comprehensive ... at a fraction of the normal cost. You can ...
Cached Biology Technology:Local TV advertising - Super Bowl vs. super bargain 2Local TV advertising - Super Bowl vs. super bargain 3Local TV advertising - Super Bowl vs. super bargain 4
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you ... remember your password, site key or the answer to your secret ... Today, Hoyos Labs , a digital infrastructure ... an end to the frustration that comes with usernames, passwords and ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... -- Studies in recent years have demonstrated that binge ... the risk of osteoporosis. Now a Loyola University ... mechanism: Alcohol disturbs genes necessary for maintaining healthy bones. ... new drugs to minimize bone loss in alcohol abusers. ...
... Zecure, a leading,provider of e-commerce fraud ... installed its award-winning Acquirer SAFE suite to,prevent ... to keep,high risk merchants under control., ... Service Providers,(PSPs) keep high-risk merchants under control ...
... along with colleagues from the California Institute of Technology, ... institutions, have unearthed crystalline magnetic fossils of a previously ... of the Paleocene and Eocene epochs, some 55 million ... the Proceedings of the National Academy of Sciences ...
Cached Biology News:Why binge drinking is bad for your bones 2OrbitalPay, LLC Implements Zecure's Acquirer SAFE Solution to Stop Fraudulent E-Commerce Merchants 2Earlier global warming produced a whole new form of life 2
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: